{"url_path":"/sec/rgen/8-k/2026-07-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/730272/0001193125-26-311402-index.html","accession_number":"0001193125-26-311402","cik":"0000730272","ticker":"RGEN","issuer_name":"REPLIGEN CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/730272/0001193125-26-311402-index.html","primary_entity_key":"0000730272","primary_entity_name":"REPLIGEN CORP"},"word_count":107,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn July 22, 2026, BioLife and Repligen issued a joint press release announcing (a) their entry into the Merger Agreement described in Item 1.01 of this Current Report on Form 8-K, (b) details for Repligen’s conference call and webcast and (c) certain financial updates as noted in Item 2.02 of this Current Report on Form 8-K. Also as noted above, a copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation accompanying such release and the conference call and webcast is attached as Exhibit 99.2 to this Current Report on Form 8-K."}